Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Coherus Biosciences, Inc. operates as a biopharmaceutical company. The Company develops biosimilar therapeutics to aid patients.
Website: coherus.com



Growth: Bad revenue growth rate -74.1%, there is slowdown compared to average historical growth rates -7.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -271.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.14 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -52.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 80.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -13.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CHRS
Share price, USD:  (0.0%)0.6409
year average price 1.6142  


year start price 1.3600 2025-11-12

max close price 2.2800 2026-01-26

min close price 0.6409 2026-11-10

current price 0.6409 2026-11-11
Common stocks: 154 500 966

Dividend Yield:  0.0%
EV / Sales: 1.8x
Margin (EBITDA LTM / Revenue): -271.7%
Fundamental value created in LTM:
Market Cap ($m): 126
Net Debt ($m): -31
EV (Enterprise Value): 95
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-13seekingalpha.com

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-23seekingalpha.com

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

2025-11-06globenewswire.com

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

2025-10-01seekingalpha.com

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

2025-08-09seekingalpha.com

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

2025-08-07globenewswire.com

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-05-12seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

2025-05-01globenewswire.com

Coherus to Participate in Upcoming Investor Conferences

2025-04-17seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

2025-03-10seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2023-11-06 2023-08-02 2023-05-08 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2025-03-17 16:28:00 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00 2022-02-23 17:29:02 2021-02-25 16:18:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 12M 10M 267M 71M 65M 77M 257M 75M 59M 32M 211M 45M 327M 476M
costOfRevenue 4M 3M 118M 21M 30M 36M 159M 33M 25M 17M 70M 35M 58M 38M
grossProfit 8M 7M 149M 50M 35M 41M 98M 42M 34M 16M 141M 10M 269M 438M
grossProfitRatio 0.678 0.669 0.707 0.545 0.532 0.561 0.577 0.48 0.224
researchAndDevelopmentExpenses 27M 26M 93M 22M 21M 27M 109M 26M 23M 34M 199M 46M 363M 143M
generalAndAdministrativeExpenses 0 0 140M 0 0 0 175M 0 0 0 188M 0 161M 135M
sellingAndMarketingExpenses 0 0 11M 0 0 0 11M 0 0 0 11M 0 9M 4M
sellingGeneralAndAdministrativeExpenses 23M 26M 150M 35M 35M 50M 186M 48M 45M 49M 198M 45M 170M 139M
otherExpenses 2M 0 17M 0 1M 3M 6M 2M 2M 2M 0 0 0 0
operatingExpenses 52M 52M 261M 56M 56M 77M 301M 74M 68M 83M 398M 91M 533M 282M
costAndExpenses 56M 56M 379M 77M 85M 113M 460M 107M 93M 100M 468M 126M 590M 320M
interestIncome 0 0 0 0 0 0 0 10M 10M 0 0 0 0 0
interestExpense 2M 2M 27M 5M 5M 11M 41M -10M 10M 10M 32M 8M 23M 21M
depreciationAndAmortization 966 000 1M 5M 2M 1M 2M 4M 899 000 880 000 2M 4M 2M 3M 5M
ebitda -41M -42M 61M -4M -6M -34M -194M -32M -32M -66M -256M -78M -261M 162M
ebitdaratio -3.563 -4.054 -0.054 -0.297 -0.444 -0.429 -0.546 -2.035 -1.72
operatingIncome -44M -45M -112M -6M -21M -36M -203M -32M -35M -68M -257M -80M -264M 156M
operatingIncomeRatio -3.831 -4.436 -0.09 -0.316 -0.464 -0.429 -0.588 -2.089 -1.771
totalOtherIncomeExpensesNet -184 000 624 000 140M -4M 8M 139M -35M -8M 2M -8M -35M -6M -23M -21M
incomeBeforeTax -45M -45M 29M -11M -13M 103M -238M -40M -43M -76M -292M -87M -287M 136M
incomeBeforeTaxRatio -3.847 -4.375 -0.152 -0.199 1.335 -0.537 -0.73 -2.335 -1.908
incomeTaxExpense 0 0 0 0 0 1M -380 000 -380 000 12M -949 000 0 6M 0 3M
netIncome -36M 298M 29M -11M -13M 103M -238M -40M -43M -75M -292M -93M -287M 132M
netIncomeRatio -3.071 29.039 -0.152 -0.199 1.335 -0.532 -0.73 -2.305 -2.044
eps -0.31 -0.36 0.25 -0.093 -0.11 0.91 -2.53 -0.41 -0.49 -0.94 -3.76 -1.19 -3.81 1.85
epsdiluted -0.31 -0.36 -0.093 -0.11 0.82 -0.41 -0.49 -0.94 -1.19
weightedAverageShsOut 116M 116M 115M 115M 115M 113M 94M 98M 87M 79M 78M 78M 75M 71M
weightedAverageShsOutDil 116M 116M 115M 115M 115M 126M 94M 98M 87M 79M 78M 78M 75M 83M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-06 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -27M -41M -32M -23M -21M
ebit 56M -198M -259M -264M 157M
nonOperatingIncomeExcludingInterest -167M -5M 2M 283 000 -554 000
netIncomeFromContinuingOperations 29M -238M -292M -287M 132M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 -3M
bottomLineNetIncome 29M -238M -292M -287M 136M
epsDiluted 0.25 -2.53 -3.76 -3.81 1.62

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2023-11-06 2023-08-02 2023-05-08 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2025-03-17 16:28:00 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00 2022-02-23 17:29:02 2021-02-25 16:18:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 103M 217M 126M 98M 159M 260M 103M 80M 73M 16M 64M 287M 417M 541M
shortTermInvestments 88M 21M 0 0 0 0 15M 51M 72M 112M 128M 0 0 0
cashAndShortTermInvestments 192M 238M 126M 98M 159M 260M 118M 131M 145M 128M 192M 287M 417M 541M
netReceivables 250M 120M 122M 199M 314M 284M 261M 217M 141M 101M 110M 91M 123M 157M
inventory 2M 5M 70M 48M 62M 62M 63M 67M 64M 114M 39M 28M 38M 44M
otherCurrentAssets 17M 18M 12M 25M 23M 22M 11M 16M 18M 21M 23M 43M 11M 0
totalCurrentAssets 461M 380M 342M 369M 558M 627M 476M 444M 385M 344M 381M 448M 602M 767M
propertyPlantEquipmentNet 2M 2M 3M 3M 3M 4M 5M 6M 7M 8M 9M 10M 8M 10M
goodwill 0 0 0 0 0 0 943 000 943 000 0 0 943 000 0 943 000 943 000
intangibleAssets 49M 52M 54M 54M 55M 57M 71M 46M 6M 0 5M 0 3M 3M
goodwillAndIntangibleAssets 49M 52M 54M 54M 55M 57M 72M 47M 6M 6M 6M 6M 4M 4M
longTermInvestments 0 0 0 0 452 000 452 000 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 -1 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 4M 5M 50M 79M 58M 74M 77M 87M 71M 45M 85M 87M 66M 60M
totalNonCurrentAssets 56M 59M 107M 136M 117M 136M 154M 139M 84M 58M 100M 103M 77M 74M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 517M 439M 449M 505M 675M 764M 630M 584M 470M 402M 481M 551M 679M 842M
accountPayables 25M 38M 28M 22M 77M 38M 35M 37M 29M 23M 12M 10M 16M 15M
shortTermDebt 2M 2M 0 2M 1M 177M 0 4M 4M 4M 0 4M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 137M 0 -4M -4M 0 0 0 0 0
otherCurrentLiabilities 347M 226M 33M 272M 385M 187M 22M 203M 140M 28M 23M 157M 22M 22M
totalCurrentLiabilities 374M 265M 283M 296M 463M 538M 332M 240M 169M 56M 139M 171M 165M 146M
longTermDebt 39M 39M 265M 232M 294M 300M 473M 474M 475M 472M 471M 477M 408M 404M
deferredRevenueNonCurrent 0 0 0 0 4M -353M 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1M 1M 1M 1M 1M 1M 1M 0 0 0 0 0 0 0
otherNonCurrentLiabilities 15M 14M 28M 65M 632 000 359M 11M 4M 102 000 72M 3M 463M 750 000 1M
totalNonCurrentLiabilities 55M 55M 298M 297M 296M 307M 491M 478M 475M 543M 480M 477M 416M 415M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 5M 2M 6M 5M 7M 6M 7M 8M 9M 10M 11M 13M
totalLiabilities 429M 320M 581M 593M 759M 845M 823M 717M 644M 599M 618M 648M 582M 561M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 12 000 12 000 12 000 12 000 12 000 11 000 11 000 11 000 9000 8000 8000 7000 7000 7000
retainedEarnings -1 345M -1 310M -1 551M -1 500M -1 490M -1 477M -1 580M -1 500M -1 460M -1 417M -1 342M -1 283M -1 050M -763M
accumulatedOtherComprehensiveIncomeLoss -203 000 -275 000 -275 000 -275 000 -272 000 -272 000 -248 000 -265 000 -297 000 -278 000 -249 000 -270 000 -270 000 -270 000
othertotalStockholdersEquity 1 433M 1 430M 1 413M 1 406M 1 395M 1 367M 1 286M 1 221M 1 186M
totalStockholdersEquity 88M 120M -132M -88M -84M -82M -193M -134M -175M -197M -137M -97M 98M 281M
totalEquity 88M 120M -132M -88M -84M -82M -193M -134M -175M -197M -137M -97M 98M 281M
totalLiabilitiesAndStockholdersEquity 517M 439M 505M 675M 764M 584M 470M 402M 551M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 517M 439M 449M 505M 675M 764M 630M 584M 470M 402M 481M 551M 679M 842M
totalInvestments 88M 21M 0 0 452 000 452 000 15M 51M 72M 112M 128M 0 0 0
totalDebt 41M 41M 270M 232M 298M 481M 481M 479M 479M 472M 480M 481M 419M 417M
netDebt -63M -176M 144M 134M 139M 221M 378M 398M 406M 455M 417M 194M 2M -124M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-06 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 111M 261M 110M 123M 157M
otherReceivables 11M 0 0 0 0
prepaids 12M 24M 18M 14M 25M
totalPayables 28M 35M 12M 16M 15M
otherPayables 0 0 0 0 0
accruedExpenses 220M 273M 100M 124M 105M
capitalLeaseObligationsCurrent 2M 2M 4M 3M 3M
capitalLeaseObligationsNonCurrent 3M 5M 5M 7M 10M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 419M 1 386M 1 204M 1 148M 1 044M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2023-11-06 2023-08-02 2023-05-08 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2025-03-17 16:28:00 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00 2022-02-23 17:29:02 2021-02-25 16:18:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -36M 298M 29M -11M -13M 103M -238M -40M -43M -76M -292M -87M -287M 132M
depreciationAndAmortization 966 000 1M 5M 2M 1M 2M 4M 899 000 880 000 949 000 4M 995 000 3M 3M
deferredIncomeTax 0 0 0 0 0 0 0 874 000 -1M 0 0 0 9M 0
stockBasedCompensation 3M 5M 28M 7M 7M 7M 43M 10M 10M 12M 51M 12M 51M 38M
changeInWorkingCapital -9M -24M 56M -63M 74M -11M -37M -28M -6M -9M -79M 9M 42M -35M
accountsReceivables -4M 55M 149M 8M 77M 9M -151M -75M -40M 9M 13M 25M 34M -15M
inventory 2M 4M -32M 21M -7M -11M -47M -19M -13M -3M -47M -23M -6M -38M
accountsPayables -15M -12M -4M -50M 39M 616 000 24M 7M 6M 12M -5M -8M 874 000 -10M
otherWorkingCapital 8M -70M -58M -41M -35M -9M 137M 60M 41M -27M -40M 15M 14M 29M
otherNonCashItems -6M -327M -138M 3M -109M -134M 53M 1M 468 000 3M 75M 28M 143M 16M
netCashProvidedByOperatingActivities -46M -47M -20M -62M 60M -47M -175M -54M -39M -69M -241M -37M -37M 154M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -286 000 0 -100 000 -152 000 -2M -457 000 -1M -7M
acquisitionsNet 0 0 0 0 228M 0 845 000 151 000 440 000 0 0 0 1M 0
purchasesOfInvestments -69M -21M 0 0 0 0 -20M 0 -20M 0 -127M 0 -182M -274M
salesMaturitiesOfInvestments 2M 0 15M 0 228M 15M 158M 43M 61M 18M 0 0 181M 274M
otherInvestingActivites -27 000 483M 444 000 -200M 188M 7M 0 178 000 0
netCashUsedForInvestingActivites -67M 463M 444 000 28M 203M 51M 41M 18M -457 000
debtRepayment 0 -233M -141 000 -187M 0 0 0 0 0
commonStockIssued 0 188 000 -976 000 633 000 2M 11M 54M 7M 0
commonStockRepurchased 0 0 0 2M 0 -745 000 0 -175 000 -305 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2000 -49M -26 000 -1M -911 000 -157 000 1M -3M 49M
netCashUsedProvidedByFinancingActivities 2000 -282M -167 000 -188M 887 000 11M 54M 4M 49M
effectOfForexChangesOnCash 0 0 0 0 0 0 -12 000 3M 0 0 0 0 0 0
netChangeInCash -114M 134M 23M -61M -101M 157M 39M 7M 57M -47M -354M 11M -124M 364M
cashAtEndOfPeriod 104M 217M 126M 98M 159M 260M 103M 81M 73M 17M 64M 287M 418M 542M
cashAtBeginningOfPeriod 217M 83M 103M 159M 260M 103M 64M 73M 17M 64M 418M 276M 542M 178M
operatingCashFlow -46M -47M -20M -62M 60M -47M -175M -54M -39M -69M -241M -37M -37M 154M
capitalExpenditure 0 0 0 0 0 0 -286 000 0 -100 000 -152 000 -2M -457 000 -1M -7M
freeCashFlow -46M -47M -20M -62M 60M -47M -175M -54M -39M -69M -243M -38M -39M 147M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-06 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 215M 6M -37M -137M -7M
netCashProvidedByInvestingActivities 230M 145M -167M -138M -14M
netDebtIssuance -223M 0 50M -672 000 222M
longTermNetDebtIssuance -223M 0 50M -672 000 222M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 1M 74M 6M -2M 0
netCommonStockIssuance 1M 74M 6M 41M 0
commonStockIssuance 1M 74M 6M 41M 0
netPreferredStockIssuance 0 0 0 -43M 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 35M -5M -2M 54M 2M
netCashProvidedByFinancingActivities -187M 70M 54M 52M 224M
incomeTaxesPaid 0 0 40 000 1M 4M
interestPaid 0 0 35M 19M 17M

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-12 ET (fiscal 2025 q1)
2024 q4
2025-03-10 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q1
2024-05-10 ET (fiscal 2024 q1)
2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-17 ET
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
2026-08-05 ET
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-22 ET
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-06-23 ET
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
2026-05-11 20:05 ET
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-04 13:30 ET
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
2026-03-09 ET
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
2026-03-02 ET
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
2026-02-23 ET
Coherus Oncology to Participate in Upcoming Investor Conferences
2026-02-17 21:11 ET
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
2026-02-13 02:18 ET
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
2026-02-12 21:05 ET
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
2026-01-06 ET
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-05 ET
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
2025-12-08 ET
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
2025-11-07 ET
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
2025-11-06 21:14 ET
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-06 ET
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
2025-10-30 ET
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-10-23 ET
Coherus Oncology to Participate in Upcoming Investor Conferences
2025-10-03 ET
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2025-09-03 ET
Coherus Oncology to Participate in Upcoming Investor Conferences
2025-08-07 ET
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-31 ET
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-05-30 ET
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
2025-05-27 ET
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
2025-05-12 ET
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-05 ET
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
2025-05-01 ET
Coherus to Participate in Upcoming Investor Conferences
2025-04-28 ET
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
2025-04-14 ET
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
2025-04-01 ET
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
2025-03-25 ET
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
2025-03-10 ET
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
2025-03-03 ET
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
2025-02-24 ET
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
2025-01-22 ET
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
2025-01-08 ET
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-18 ET
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
2024-12-03 ET
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
2024-11-27 ET
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
2024-11-06 21:01 ET
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-30 20:20 ET
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
2024-08-08 20:05 ET
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-01 13:00 ET
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-06-27 12:26 ET
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
2024-06-05 13:00 ET
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
2024-05-30 13:00 ET
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
2024-05-23 21:51 ET
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024-05-23 13:00 ET
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
2024-05-09 20:01 ET
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-09 11:30 ET
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
2024-05-09 11:30 ET
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
2024-05-08 13:00 ET
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
2024-05-01 20:30 ET
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
2024-04-24 14:02 ET
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024-04-08 12:30 ET
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
2024-03-13 20:01 ET
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 21:01 ET
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 06:00 ET
Coherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 22:33 ET
Coherus BioSciences Announces New Employment Inducement Grants
2024-02-21 13:30 ET
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 13:00 ET
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 06:15 ET
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-22 ET
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 21:05 ET
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-03 14:00 ET
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 13:29 ET
Coherus Announces U.S. Launch of LOQTORZI™
2023-12-26 21:01 ET
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 22:00 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-12-11 13:30 ET
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 22:55 ET
Coherus BioSciences Announces CFO Transition Plans
2023-12-06 09:00 ET
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 16:16 ET
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Ass...
2023-11-06 21:07 ET
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
2023-11-03 12:30 ET
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
2023-11-03 00:00 ET
Coherus BioSciences to Participate at Upcoming November Investor Conferences
2023-10-30 22:00 ET
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-10-27 19:07 ET
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2023-10-24 23:41 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-10-14 16:30 ET
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-05 12:30 ET
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
2023-10-04 12:30 ET
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
2023-10-02 13:00 ET
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
2023-09-27 13:10 ET
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2023-09-25 12:30 ET
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
2023-09-23 01:00 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-09-08 13:05 ET
Coherus Completes Surface Oncology Acquisition
2023-09-01 20:01 ET
Coherus BioSciences to Participate at Upcoming September Investor Conferences
2023-08-31 20:01 ET
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
2023-08-22 21:35 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-08-02 20:01 ET
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
2023-07-26 20:05 ET
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
2023-07-21 21:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-07-20 20:04 ET
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
2023-07-13 12:30 ET
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
2023-07-03 12:30 ET
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
2023-07-03 ET
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
2023-06-27 01:08 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-06-16 11:01 ET
Coherus to Acquire Surface Oncology
2023-06-05 21:30 ET
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
2023-06-01 12:33 ET
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
2023-06-01 12:30 ET
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
2023-05-22 12:30 ET
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
2023-05-16 10:50 ET
Coherus Prices Public Offering of Common Stock
2023-05-15 20:01 ET
Coherus Announces Proposed Public Offering of Common Stock
2023-05-08 20:05 ET
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
2023-05-04 20:30 ET
Coherus BioSciences to Present at Upcoming Investor Conferences in May
2023-05-01 20:07 ET
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
2023-04-27 12:05 ET
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-03-06 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
2023-03-06 13:00 ET
FDA Approves UDENYCA® Autoinjector
2023-03-01 13:25 ET
Coherus BioSciences to Present at Upcoming Investor Conferences in March
2023-02-28 13:25 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
2023-02-15 13:25 ET
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
2023-02-13 13:25 ET
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
2023-02-03 22:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2023-01-09 13:20 ET
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
2023-01-04 12:01 ET
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-25 13:16 ET
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2022-12-24 05:01 ET
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2022-11-08 21:01 ET
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
2022-11-01 11:30 ET
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
2022-10-12 11:30 ET
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical...
2022-09-19 11:30 ET
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
2022-09-12 12:30 ET
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-08-30 00:49 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-08-04 20:01 ET
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
2022-08-02 23:15 ET
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
2022-08-02 03:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-07-28 20:01 ET
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
2022-07-06 12:00 ET
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
2022-06-22 20:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-05-11 22:00 ET
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
2022-05-10 12:45 ET
Coherus BioSciences Management to Present at Upcoming Investor Conferences
2022-05-05 20:01 ET
Coherus BioSciences Reports First Quarter 2022 Results
2022-05-05 12:31 ET
Coherus BioSciences Appoints Charlie Newton to Board of Directors
2022-05-04 01:44 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-05-02 11:00 ET
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
2022-04-29 12:45 ET
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
2022-04-14 12:30 ET
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
2022-04-08 17:10 ET
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
2022-04-05 20:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-03-29 13:15 ET
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
2022-03-22 20:30 ET
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
2022-03-15 12:00 ET
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
2022-03-15 11:30 ET
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
2022-03-04 21:05 ET
Coherus Management to Present at Upcoming Investor Conferences
2022-03-04 13:00 ET
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
2022-02-17 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
2022-02-15 21:30 ET
Coherus Names Paul Reider Chief Commercial Officer
2022-02-14 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2022-02-11 13:30 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
2022-02-07 13:30 ET
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
2022-01-10 12:30 ET
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
2022-01-07 13:30 ET
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
2022-01-04 13:32 ET
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-20 12:59 ET
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
2021-12-17 14:09 ET
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
2021-12-16 21:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-12-13 12:00 ET
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-11-15 13:30 ET
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
2021-11-10 21:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-11-08 21:01 ET
Coherus BioSciences Reports Third Quarter 2021 Results
2021-11-05 12:30 ET
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
2021-11-01 11:30 ET
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
2021-11-01 11:30 ET
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
2021-10-29 20:11 ET
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
2021-10-11 12:30 ET
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
2021-10-05 12:00 ET
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
2021-10-04 12:00 ET
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annua...
2021-10-01 17:09 ET
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
2021-09-29 20:30 ET
Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
2021-09-24 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-09-16 22:28 ET
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal...
2021-09-15 12:30 ET
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
2021-09-14 00:35 ET
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
2021-09-10 12:45 ET
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-08 12:30 ET
Coherus BioSciences Announces Upcoming Medical Conference Presentations
2021-09-01 12:01 ET
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
2021-08-27 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-08-19 01:09 ET
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-08-18 22:41 ET
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
2021-08-12 12:01 ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
2021-08-12 12:01 ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
2021-08-05 20:01 ET
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
2021-07-26 20:31 ET
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
2021-07-21 13:15 ET
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
2021-07-13 00:29 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-06-04 20:01 ET
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
2021-06-04 00:45 ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2021-06-03 21:00 ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2021-05-07 20:01 ET
Coherus BioSciences to Present at the Bank of America Health Care Conference
2021-05-06 20:01 ET
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
2021-04-30 20:15 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-04-30 12:15 ET
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
2021-04-29 11:30 ET
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
2021-04-23 12:00 ET
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
2021-04-20 12:00 ET
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
2021-03-03 11:45 ET
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
2021-02-25 13:45 ET
Coherus Management to Present at Upcoming Investor Conferences
2021-02-24 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-18 13:30 ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
2021-02-17 12:30 ET
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
2021-02-16 13:00 ET
Coherus Announces CFO Transition Plans
2021-02-02 13:30 ET
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
2021-02-02 13:30 ET
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
2021-02-01 12:53 ET
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
2021-02-01 10:30 ET
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada
2021-01-22 21:01 ET
Coherus BioSciences Announces New Employment Inducement Grants
2021-01-07 21:01 ET
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
2021-01-05 21:01 ET
Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-21 21:02 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-11-20 21:01 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-11-05 21:02 ET
Coherus BioSciences Reports Third Quarter 2020 Financial Results
2020-10-22 20:15 ET
Coherus BioSciences to Report Third Quarter Financial Results on November 5th
2020-10-16 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-09-18 15:02 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-08-21 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-08-06 20:02 ET
Coherus BioSciences Reports Second Quarter 2020 Financial Results
2020-08-03 20:48 ET
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
2020-07-17 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-07-16 13:30 ET
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
2020-06-19 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-05-07 20:08 ET
Coherus BioSciences Reports First Quarter 2020 Financial Results
2020-05-04 13:30 ET
Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
2020-04-22 13:30 ET
Coherus BioSciences to Report First Quarter Financial Results on May 7th
2020-04-15 04:05 ET
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
2020-04-14 11:52 ET
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
2020-04-13 13:22 ET
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
2020-03-20 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-03-05 21:09 ET
Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
2020-03-05 12:00 ET
United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand
2020-02-27 21:01 ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26 14:30 ET
Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
2020-02-20 16:19 ET
Coherus BioSciences Announces New Employment Inducement Grants
2020-02-06 14:34 ET
Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th
2020-01-13 13:30 ET
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
2020-01-03 14:30 ET
Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-12 14:30 ET
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
2019-11-08 14:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-11-06 21:01 ET
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results
2019-11-06 21:01 ET
Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
2019-10-18 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-10-15 13:30 ET
Coherus BioSciences to Report Third Quarter Financial Results on November 6th
2019-09-20 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-04-19 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-04-08 13:31 ET
Thinking about buying stock in Aurora Cannabis Inc., Chesapeake Energy Corp., Coherus Biosciences Inc., Snap Inc., or Vital Therapies Inc.
2019-04-05 20:00 ET
Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales
2019-04-05 12:30 ET
Coherus BioSciences to Report First Quarter Financial Results on May 9th
2019-03-28 13:30 ET
Coherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference
2019-03-22 13:30 ET
Coherus BioSciences Announces New Employment Inducement Grants
2019-03-08 12:00 ET
Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights

SEC forms

Show financial reports only

SEC form 10
2026-11-09 00:00 ET
Coherus Biosciences reported for 2026 q3
SEC form 8
2026-11-09 00:00 ET
Coherus Biosciences published news for 2026 q3
SEC form 8
2026-11-09 00:00 ET
Coherus Biosciences published news for 2026 q3
SEC form 8
2026-08-17 21:28 ET
Coherus Biosciences published news for 2026 q2
SEC form 8
2026-08-17 21:28 ET
Coherus Biosciences published news for 2026 q2
SEC form 8
2026-08-17 21:28 ET
Coherus Biosciences published news for 2026 q2
SEC form 8
2026-08-17 21:28 ET
Coherus Biosciences published news for 2026 q2
SEC form 10
2026-08-05 21:14 ET
Coherus Biosciences reported for 2026 q2
SEC form 8
2026-08-05 20:43 ET
Coherus Biosciences published news for 2026 q2
SEC form 8
2026-08-05 20:43 ET
Coherus Biosciences published news for 2026 q2
SEC form 8
2026-06-15 20:40 ET
Coherus Biosciences published news for 2026 q1
SEC form 8
2026-06-15 20:40 ET
Coherus Biosciences published news for 2026 q1
SEC form 10
2026-05-11 20:43 ET
Coherus Biosciences reported for 2026 q1
SEC form 8
2026-05-11 20:16 ET
Coherus Biosciences published news for 2026 q1
SEC form 8
2026-05-11 20:16 ET
Coherus Biosciences published news for 2026 q1
SEC form 10
2026-03-09 20:56 ET
Coherus Biosciences reported for 2025 q4
SEC form 8
2026-03-09 20:40 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-03-09 20:40 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-02-17 21:05 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-02-17 21:05 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-02-17 21:05 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-01-23 17:27 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-01-23 17:27 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-01-13 14:00 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2026-01-13 14:00 ET
Coherus Biosciences published news for 2025 q4
SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 10
2025-11-06 17:12 ET
Coherus Biosciences reported for 2025 q3
SEC form 8
2025-11-06 16:28 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-06 16:28 ET
Coherus Biosciences reported for 2025 q3
SEC form 10
2025-08-07 20:55 ET
Coherus Biosciences reported for 2025 q2
SEC form 8
2025-08-07 20:53 ET
Coherus Biosciences published news for 2025 q2
SEC form 8
2025-08-07 20:53 ET
Coherus Biosciences reported for 2025 q2
SEC form 10
2025-05-12 20:59 ET
Coherus Biosciences reported for 2025 q1
SEC form 8
2025-05-12 20:39 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-05-12 20:39 ET
Coherus Biosciences reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Coherus Biosciences reported for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 10
2025-03-17 20:28 ET
Coherus Biosciences published news for 2024 q4
SEC form 10
2025-03-17 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-03-10 16:31 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-03-10 16:31 ET
Coherus Biosciences reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 10
2024-11-06 16:31 ET
Coherus Biosciences reported for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Coherus Biosciences published news for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Coherus Biosciences published news for 2024 q3
SEC form 10
2024-08-08 16:39 ET
Coherus Biosciences reported for 2024 q2
SEC form 8
2024-08-08 16:23 ET
Coherus Biosciences published news for 2024 q2
SEC form 8
2024-08-08 16:23 ET
Coherus Biosciences published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Coherus Biosciences published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Coherus Biosciences reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Coherus Biosciences published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Coherus Biosciences published news for 2024 q1
SEC form 10
2024-03-15 17:13 ET
Coherus Biosciences published news for 2023 q4
SEC form 10
2024-03-15 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences reported for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 10
2023-11-06 16:35 ET
Coherus Biosciences reported for 2023 q3
SEC form 8
2023-11-06 16:31 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-08-02 16:11 ET
Coherus Biosciences reported for 2023 q2
SEC form 6
2023-08-02 16:05 ET
Coherus Biosciences published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:10 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:01 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-06-16 07:06 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-15 06:05 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-09 17:01 ET
Coherus Biosciences published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-03-28 18:48 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2023-03-06 16:16 ET
Coherus Biosciences published news for 2022 q4
SEC form 6
2023-03-06 16:11 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 6
2023-01-12 19:42 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2022-11-08 16:03 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-11-08 16:01 ET
Coherus Biosciences published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 6
2022-10-06 16:06 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-09-15 16:34 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 17:36 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 16:46 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:35 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-08-04 16:25 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 6
2022-05-20 17:18 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-20 16:50 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-13 16:44 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-10 16:58 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:47 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:43 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 16:38 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-05 16:28 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Coherus Biosciences reported for 2022 q1
SEC form 6
2022-04-04 16:05 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-04-01 16:16 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-02-23 17:29 ET
Coherus Biosciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-17 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-07 17:17 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-04 20:19 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-13 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-07 08:36 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2021-12-03 17:28 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 16:11 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-11-08 16:06 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-10-13 17:01 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-09-29 17:07 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-11 16:04 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 16:19 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-05 16:06 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-05-26 06:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 16:31 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-05-06 16:24 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-04-09 16:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-03-16 18:10 ET
Coherus Biosciences published news for 2020 q4
SEC form 10
2021-02-25 16:18 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-24 16:05 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-12 16:41 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-02 08:45 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:32 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:30 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:15 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2020-11-18 16:06 ET
Coherus Biosciences published news for 2020 q3
SEC form 10
2020-11-05 16:17 ET
Coherus Biosciences published news for 2020 q3
SEC form 6
2020-11-05 16:07 ET
Coherus Biosciences published news for 2020 q3